Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.55 |
| ▸ | NAMPT | P43490 | 1/20 | 0.52 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.49 |
| ▸ | GRM1 | Q13255 | 10/20 | 0.48 |
| ▸ | GRM5 | P41594 | 9/20 | 0.48 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | WNT3A | P56704 | 1/20 | 0.46 |
| ▸ | ATR | Q13535 | 1/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.45 |
| ▸ | CDK7 | P50613 | 1/20 | 0.45 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.45 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22324763 | 0.89 | NAMPT (0.53) | GPR119NAMPTCYP11B2GRM1GRM5 | |
| SCHEMBL29580437 | 0.89 | NAMPT (0.53) | GPR119NAMPTCYP11B2GRM1GRM5 | |
| SCHEMBL31510790 | 0.87 | NAMPT (0.52) | GPR119NAMPTCYP11B2GRM1GRM5 | |
| SCHEMBL29071631 | 0.85 | NAMPT (0.50) | NAMPTCYP11B2GRM1GRM5PDK4 | |
| SCHEMBL30487298 | 0.85 | NAMPT (0.50) | NAMPTCYP11B2GRM1GRM5PDK4 | |
| SCHEMBL23306173 | 0.84 | NAMPT (0.55) | NAMPTCYP11B2GRM1GRM5PDK4 | |
| SCHEMBL29840400 | 0.84 | NAMPT (0.55) | NAMPTCYP11B2GRM1GRM5PDK4 | |
| SCHEMBL29891644 | 0.84 | NAMPT (0.55) | NAMPTCYP11B2GRM1GRM5PDK4 | |
| SCHEMBL29840385 | 0.84 | NAMPT (0.55) | NAMPTCYP11B2GRM1GRM5PDK4 | |
| SCHEMBL15095872 | 0.84 | NAMPT (0.55) | NAMPTCYP11B2GRM1GRM5PDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2794587-B1 | NEW PIPERIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2016-03-16 | — | — | EP | disclosed |
| US-8765959-B2 | Piperidine derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-01 | — | — | US | disclosed |
| US-8765959-B2 | Piperidine derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-01 | — | — | US | disclosed |
| US-8765959-B2 | Piperidine derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-01 | — | — | US | disclosed |
| US-20130165444-A1 | Piperidine Derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-27 | — | — | US | disclosed |
| US-20130165444-A1 | Piperidine Derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165444-A1 | Piperidine Derivatives | PPARD, FABP4, PLIN5 | GPR119 5/4885NAMPT 372/4885CYP11B2 1159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.